|Study Title:||A Multi-site Randomized Controlled Trial of MS INFoRm: An Interactive Fatigue Management Resource for Persons with Multiple Sclerosis|
|Study Description:||People with MS commonly experience extreme fatigue that negatively impacts their ability to engage in a full range of daily activities, quality of life, and employment. Currently available treatments for fatigue in MS are limited by their lack of individualization and access. The proposed study will provide crucial evidence about the potential of MS INFoRm as a self- management tool that can be made widely available to persons with MS as a means to effectively reduce the daily impact of MS fatigue.
People with MS commonly experience extreme fatigue that negatively impacts their ability to engage in a full range of daily activities. A new fatigue management website called “MS INFoRm” allows people with MS to take a personalized and active approach to learning about and managing their fatigue. Although pilot findings look promising, more rigorous evaluation using a randomized controlled trial is needed to determine if this new website is indeed efficacious and effective for reducing the impact of fatigue among persons with MS, and improving secondary outcomes of self-efficacy, self-reported cognitive function, participation and autonomy, and depression. Two hundred participants from across Canada will be randomly assigned to one of two groups: the experimental (MS INFoRm) group or usual care control group. Both groups will be evaluated by telephone interview on primary (fatigue impact) and secondary (self-efficacy, cognitive function, participation and autonomy, depression) outcomes at baseline (week 1), after 3-month use of the MS INFoRm website (week 12), and after 6-month follow-up (week 36).
|Who can participate:||Individuals with a confirmed diagnosis of MS, between 18 to 65 years of age, having access to a computer or other electronic device with internet access, reporting mild to moderate fatigue, and living in Canada|
|Location of Trial:||Ontario|
|Contact Information:||Dr. Marcia Finlayson
|Trial Funding:||Multiple Sclerosis Society of Canada|